LUXIQ AEROSOL, FOAM

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

BETAMETHASONE VALERATE

متاح من:

MAYNE PHARMA INC

ATC رمز:

D07AC01

INN (الاسم الدولي):

BETAMETHASONE

جرعة:

0.12%

الشكل الصيدلاني:

AEROSOL, FOAM

تركيب:

BETAMETHASONE VALERATE 0.12%

طريقة التعاطي:

TOPICAL

الوحدات في الحزمة:

12/50/100G

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

ANTI-INFLAMMATORY AGENTS

ملخص المنتج:

Active ingredient group (AIG) number: 0106302004; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2020-01-09

خصائص المنتج

_ _
_ _
_ _
_ _
_LUXIQ_
_®_
_ (betamethasone valerate) Product Monograph _
_Page 1 of 26_
PRODUCT MONOGRAPH
Pr
LUXIQ
®
betamethasone valerate
Foam, 0.12% w/w
Topical Corticosteroid Therapy
Mayne Pharma Inc.
1240 Sugg Parkway
Greenville, NC 27834
USA
Date of Revision:
March 2, 2018
Imported/Distributed by:
C.R.I.
Dundas, ON L9H 7P3
Submission Control No: 212951
_ _
_ _
_ _
_ ®_
_LUXIQ is a registered trade-mark used under license by Mayne Pharma
Inc. _
_ _
_ _
_ _
_ _
_LUXIQ_
_®_
_ (betamethasone valerate) Product Monograph _
_Page 2 of 26_
TABLE OF CONTENTS
PAGE
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT
INFORMATION.............................................................................
3
INDICATIONS AND CLINICAL USE
..................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
......................................................................................
4
ADVERSE REACTIONS
........................................................................................................
8
DRUG INTERACTIONS
......................................................................................................
10
DOSAGE AND ADMINISTRATION
..................................................................................
11
OVERDOSAGE
.....................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 13
STORAGE AND STABILITY
..............................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
............................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................